TKNO teknova.com: Company Value to Revenue

Official company branding of Teknova (TKNO)

A steady inflow of funds from the sale of biopharma reagents creates a reliable foundation for Alpha Teknova, Inc. (TKNO). On GURU.Markets, the historical EV/Sales level confirms this momentum, with the current value equal to 10918.61. Recurring purchases of consumables maintain operational momentum, although global raw material logistics disruptions and sanctions may temporarily limit the company's export of biological media.

teknova.com (TKNO): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

TKNO (Teknova Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:TKNO - teknova.com
Manufactured products of Alpha Teknova Inc

Alpha Teknova, Inc. (TKNO) maintains stabilized cash flows due to its broad client diversification within the biopharmaceutical sector. An analysis of the enterprise value-to-revenue multiple allows for an assessment of the business's market value excluding debt load. This metric compares the total enterprise value to sales volume, revealing the actual efficiency of capitalization. This chart helps determine if the asset is overbought relative to revenue growth rates, which is critical for preventing capital freeze during periods of inflated market expectations.

Competitor analysis

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple